BRCA1-associated protein inhibits glioma cell proliferation and migration and glioma stem cell self-renewal via the TGF-β/PI3K/AKT/mTOR signalling pathway

[1]  C. Blanpain,et al.  EMT Transition States during Tumor Progression and Metastasis. , 2019, Trends in cell biology.

[2]  I. Choi,et al.  Associations of BRAP polymorphisms with the risk of alcohol dependence and scores on the Alcohol Use Disorders Identification Test , 2018, Neuropsychiatric disease and treatment.

[3]  J. Marjanovic Vicentic,et al.  SOX3 can promote the malignant behavior of glioblastoma cells , 2018, Cellular Oncology.

[4]  Robert A. Weinberg,et al.  EMT in cancer , 2018, Nature Reviews Cancer.

[5]  Linna Peng,et al.  BRCA1-Associated Protein Increases Invasiveness of Esophageal Squamous Cell Carcinoma. , 2017, Gastroenterology.

[6]  M. Shirouzu,et al.  Central catalytic domain of BRAP (RNF52) recognizes the types of ubiquitin chains and utilizes oligo-ubiquitin for ubiquitylation , 2017, The Biochemical journal.

[7]  C. M. Roth,et al.  Crosstalk between M2 macrophages and glioma stem cells , 2017, Cellular Oncology.

[8]  A. Sarmento-Ribeiro,et al.  Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition , 2017, Cellular Oncology.

[9]  Katharine A McNeill,et al.  Epidemiology of Brain Tumors. , 2016, Neurologic clinics.

[10]  Christopher P. Fischer,et al.  Genome-wide association study of colorectal cancer identifies six new susceptibility loci , 2015, Nature Communications.

[11]  H. Fine,et al.  Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date , 2015, Cancer.

[12]  Jean J. Zhao,et al.  PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting , 2014, Nature Reviews Cancer.

[13]  M Brada,et al.  High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Jiri Polivka,et al.  Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. , 2014, Pharmacology & therapeutics.

[15]  Ryan A. Grant,et al.  Molecular and genetic pathways in gliomas: the future of personalized therapeutics. , 2014, CNS oncology.

[16]  C. Rommel,et al.  PI3K and cancer: lessons, challenges and opportunities , 2014, Nature Reviews Drug Discovery.

[17]  Dai Zhang,et al.  A Two-Stage Association Study Suggests BRAP as a Susceptibility Gene for Schizophrenia , 2014, PloS one.

[18]  P. ten Dijke,et al.  Signaling interplay between transforming growth factor-β receptor and PI3K/AKT pathways in cancer. , 2013, Trends in biochemical sciences.

[19]  K. Loveland,et al.  The BRCA1-binding protein BRAP2 can act as a cytoplasmic retention factor for nuclear and nuclear envelope-localizing testicular proteins. , 2013, Biochimica et biophysica acta.

[20]  J. Mi,et al.  The single nucleotide polymorphisms in BRAP decrease the risk of metabolic syndrome in a Chinese young adult population , 2013, Diabetes & vascular disease research.

[21]  G. Wang,et al.  Prognostic significance of BRCA1-associated protein 1 in colorectal cancer , 2013, Medical Oncology.

[22]  Han Liu,et al.  Direct and Indirect Control of Mitogen-activated Protein Kinase Pathway-associated Components, BRAP/IMP E3 Ubiquitin Ligase and CRAF/RAF1 Kinase, by the Deubiquitylating Enzyme USP15 , 2012, The Journal of Biological Chemistry.

[23]  Toshihiro Tanaka,et al.  BRAP Activates Inflammatory Cascades and Increases the Risk for Carotid Atherosclerosis , 2011, Molecular medicine.

[24]  G. Alvisi,et al.  The BRCA‐1 binding protein BRAP2 is a novel, negative regulator of nuclear import of viral proteins, dependent on phosphorylation flanking the nuclear localization signal , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  J. Baselga,et al.  Status of PI3K inhibition and biomarker development in cancer therapeutics. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  M. White,et al.  Signaling Threshold Regulation by the Ras Effector IMP* , 2009, Journal of Biological Chemistry.

[27]  Yusuke Nakamura,et al.  SNPs in BRAP associated with risk of myocardial infarction in Asian populations , 2009, Nature Genetics.

[28]  R. Flavell,et al.  p21 Ras/Impedes Mitogenic Signal Propagation Regulates Cytokine Production and Migration in CD4 T Cells* , 2008, Journal of Biological Chemistry.

[29]  D. Rowitch,et al.  Glioma Stem Cells: A Midterm Exam , 2008, Neuron.

[30]  Robert E. Lewis,et al.  IMP Modulates KSR1-dependent Multivalent Complex Formation to Specify ERK1/2 Pathway Activation and Response Thresholds* , 2008, Journal of Biological Chemistry.

[31]  R. Gilbertson,et al.  Making a tumour's bed: glioblastoma stem cells and the vascular niche , 2007, Nature Reviews Cancer.

[32]  S. Enosawa,et al.  Brap2 Functions as a Cytoplasmic Retention Protein for p21 during Monocyte Differentiation , 2004, Molecular and Cellular Biology.

[33]  Robert E. Lewis,et al.  Ras regulates assembly of mitogenic signalling complexes through the effector protein IMP , 2004, Nature.

[34]  F. Davis,et al.  Epidemiology of brain tumors. , 2000, Current opinion in neurology.

[35]  Wen-Hwa Lee,et al.  Identification of a Novel Cytoplasmic Protein That Specifically Binds to Nuclear Localization Signal Motifs* , 1998, The Journal of Biological Chemistry.

[36]  Selene M. Virk,et al.  Epidemiology of Intracranial Gliomas. , 2018, Progress in neurological surgery.

[37]  M. White,et al.  Ras-sensitive IMP modulation of the Raf/MEK/ERK cascade through KSR1. , 2006, Methods in enzymology.

[38]  Andreas Platzer.  Midterm I Exam , 2001 .